Treatment of the barbiturate abstinence syndrome
- PMID: 3773832
Treatment of the barbiturate abstinence syndrome
Abstract
Patients with the barbiturate abstinence syndrome require pharmacotherapy (and hospitalization) when there is a history of the ingestion of greater than 0.4 g of secobarbital or its equivalent for 90 or more days, or of 0.6 g for 30 or more days, or a previous history of barbiturate withdrawal seizures or delirium. The pharmacological management of withdrawal, which is rational, safe, efficacious and relatively simple, is described and recommended. This treatment relies on a phenobarbital loading-dose technique which is titrated to clinical end-points. The prolonged elimination of phenobarbital prevents the reappearance of withdrawal symptoms and, since repeated doses are not required, results in less manipulative drug-seeking behaviour.
Similar articles
-
Oral phenobarbital loading: a safe method of barbiturate and nonbarbiturate hypnosedative withdrawal.CMAJ. 1987 Sep 1;137(5):410-2. CMAJ. 1987. PMID: 3621099 Free PMC article.
-
A new method for treatment of barbiturate dependence.JAMA. 1970 Jul 13;213(2):294-5. JAMA. 1970. PMID: 5467903 No abstract available.
-
Investigation of clonidine and lofexidine for the treatment of barbiturate withdrawal in mice.Vet Hum Toxicol. 1985 Dec;27(6):503-5. Vet Hum Toxicol. 1985. PMID: 4082462
-
Barbiturate tolerance and physical dependence: contribution of pharmacological factors.NIDA Res Monogr. 1984;54:333-47. NIDA Res Monogr. 1984. PMID: 6442760 Review. No abstract available.
-
Abuse liability of barbiturates and other sedative-hypnotics.Adv Alcohol Subst Abuse. 1990;9(1-2):67-82. doi: 10.1300/J251v09n01_05. Adv Alcohol Subst Abuse. 1990. PMID: 2198786 Review.
Cited by
-
Rebound effect, discontinuation, and withdrawal syndromes associated with drugs used in psychiatric and neurological disorders.Pharmacol Rep. 2025 Apr;77(2):303-314. doi: 10.1007/s43440-024-00689-z. Epub 2024 Dec 23. Pharmacol Rep. 2025. PMID: 39710834 Review.
-
Genetic Addiction Risk Severity Assessment Identifies Polymorphic Reward Genes as Antecedents to Reward Deficiency Syndrome (RDS) Hypodopaminergia's Effect on Addictive and Non-Addictive Behaviors in a Nuclear Family.J Pers Med. 2022 Nov 8;12(11):1864. doi: 10.3390/jpm12111864. J Pers Med. 2022. PMID: 36579592 Free PMC article.
-
Should butalbital-containing analgesics be banned? Yes.Curr Pain Headache Rep. 2002 Apr;6(2):151-5. doi: 10.1007/s11916-002-0012-y. Curr Pain Headache Rep. 2002. PMID: 11872187 Review.
-
Hypertension and pulmonary oedema associated with ketamine administration in a patient with a history of substance abuse.Can J Anaesth. 1993 Feb;40(2):160-4. doi: 10.1007/BF03011314. Can J Anaesth. 1993. PMID: 8443855
-
Alcohol, barbiturate and benzodiazepine withdrawal syndromes: clinical management.CMAJ. 1988 Jul 15;139(2):113-20. CMAJ. 1988. PMID: 2898972 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources